Ontology highlight
ABSTRACT:
SUBMITTER: Verma S
PROVIDER: S-EPMC2722048 | biostudies-literature | 2009 Jul
REPOSITORIES: biostudies-literature
Verma S S Sehdev S S Joy A A Madarnas Y Y Younus J J Roy J A JA
Current oncology (Toronto, Ont.) 20090701
The third-generation aromatase inhibitors (AIS) are largely replacing tamoxifen in the adjuvant treatment of early-stage breast cancer in postmenopausal women with hormone receptor-positive tumours. To date, multiple trials have been conducted comparing tamoxifen treatment with an AI, and all have demonstrated improved disease-free survival with AI treatment. Trials have included direct 5-year comparisons between tamoxifen and an AI, switching to an AI within 5 years after initial tamoxifen trea ...[more]